- Home
- SHMD vs ABOS Comparison
SHMD vs ABOS Comparison
Compare SHMD & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHMD
- ABOS
- Stock Information
- Founded
- SHMD 1864
- ABOS 1996
- Country
- SHMD Germany
- ABOS United States
- Employees
- SHMD N/A
- ABOS N/A
- Industry
- SHMD
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- SHMD
- ABOS Health Care
- Exchange
- SHMD Nasdaq
- ABOS Nasdaq
- Market Cap
- SHMD 144.3M
- ABOS 99.1M
- IPO Year
- SHMD N/A
- ABOS 2021
- Fundamental
- Price
- SHMD $2.58
- ABOS $1.56
- Analyst Decision
- SHMD
- ABOS Strong Buy
- Analyst Count
- SHMD 0
- ABOS 3
- Target Price
- SHMD N/A
- ABOS $9.33
- AVG Volume (30 Days)
- SHMD 51.8K
- ABOS 379.4K
- Earning Date
- SHMD 02-25-2025
- ABOS 11-12-2024
- Dividend Yield
- SHMD N/A
- ABOS N/A
- EPS Growth
- SHMD 1309.32
- ABOS N/A
- EPS
- SHMD 1.07
- ABOS N/A
- Revenue
- SHMD $99,752,404.00
- ABOS N/A
- Revenue This Year
- SHMD N/A
- ABOS N/A
- Revenue Next Year
- SHMD N/A
- ABOS N/A
- P/E Ratio
- SHMD $2.30
- ABOS N/A
- Revenue Growth
- SHMD N/A
- ABOS N/A
- 52 Week Low
- SHMD $1.98
- ABOS $1.54
- 52 Week High
- SHMD $6.13
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- SHMD N/A
- ABOS 30.29
- Support Level
- SHMD N/A
- ABOS $1.69
- Resistance Level
- SHMD N/A
- ABOS $1.88
- Average True Range (ATR)
- SHMD 0.00
- ABOS 0.13
- MACD
- SHMD 0.00
- ABOS -0.00
- Stochastic Oscillator
- SHMD 0.00
- ABOS 4.88
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.